Aimmune Therapeutics Inc AIMT:NASDAQ

Last Price$18.09NASDAQ Closing Price as of 4:00PM ET 7/18/19

Today's Change-0.90(4.74%)
Bid (Size)$18.02 (2)
Ask (Size)$22.10 (5)
Day Low / High$18.02 - 19.06
Volume809.0 K
  • Latest Stories
  • Commentary and Analysis
Sector Update: Health Care Stocks Struggle This Afternoon
4:00PM ET 7/11/2019 MT Newswires

Top Health Care Stocks JNJ -0.96% PFE -2.60% ABT +0.17% MRK -4.42% AMGN -2.29% Health care stocks continued to decline on Thursday, with the NYSE...

Sector Update: Health Care
3:47PM ET 7/11/2019 MT Newswires

Health care stocks continued to decline on Thursday, with the NYSE Health Care Index dropping almost 0.3% in late trade while shares of health care...

Aimmune Therapeutics Hits Back at ICER Report on Desensitization Treatments for Peanut Allergy; Shares Fall 9%
2:03PM ET 7/11/2019 MT Newswires

Shares of Aimmune Therapeutics (AIMT) dropped 9% intraday after the firm hit back against a report on emerging desensitization treatments for peanut...

Aimmune Therapeutics Submits EU Marketing Authorization Application for Peanut Allergy Drug
7:34AM ET 6/28/2019 MT Newswires

Aimmune Therapeutics (AIMT) said it has submitted a marketing authorization application to the European Medicines Agency for AR101, an investigational...

Aimmune Therapeutics to Discuss AR101's Cost-Effectiveness for Peanut Allergy Treatment at ICER Meeting
9:30AM ET 6/11/2019 MT Newswires

Shares of Aimmune Therapeutics (AIMT) were down 1.34% pre-market as the company announced plans to discuss the effectiveness and value of treatments for...

Aimmune Therapeutics Presents New Data From Follow-On Study of AR101 for Peanut Allergy
8:12AM ET 6/04/2019 MT Newswires

Aimmune Therapeutics (AIMT) said Tuesday that new data from a follow-on study of its peanut allergy drug AR101 showed that extending daily therapy with...

Analyst Actions: Credit Suisse Cuts Aimmune Therapeutics PT to $30 from $36, Assumes Coverage at Outperform on Peanut Allergy Drug - Stock Up 3%
2:04PM ET 5/21/2019 MT Newswires

Credit Suisse has cut its price target on Aimmune Therapeutics (AIMT) to $30 from $36 while assuming its outperform rating, betting on its current...

Aimmune Therapeutics' Peanut Allergy Drug Set for FDA Review Meeting Sept. 13
2:40PM ET 5/16/2019 MT Newswires

Aimmune Therapeutics (AIMT) said the US Food and Drug Administration will review the application for its peanut allergy drug at a Sept. 13 meeting. The...

Analyst Actions: Aimmune Therapeutics' PT Raised to $79 at Wedbush, Outperform Rating Reiterated
12:32PM ET 3/26/2019 MT Newswires

Aimmune Therapeutics' (AIMT) price target increased to $79 from $76 at Wedbush, in light of the ARTEMIS trial's positive topline results. The Artemis...

Analyst Actions: RBC Capital Lifts Aimmune Therapeutics PT to $58 From $55; Maintains Outperform Rating
9:35AM ET 3/26/2019 MT Newswires

RBC Capital said it has raised Aimmune Therapeutics' (AIMT) price target to $58 from $55, while reiterating its outperform rating. According to the broker,...